Here are five insights:
1. Amend Surgical’s portfolio also includes an FDA-cleared demineralized bone matrix and bioactive glass combination.
2. The acquisition will boost KICVentures’ NanoFuse Biologics company.
3. During the transition, Amend Surgical will manufacture the NanoFuse Bioactive Matrix.
4. The NanoFuse Bioactive Matrix combines osteoinductive capabilities of demineralized bone with osteostimulative properties of bioactive glass.
5. Orthopedic surgeon Kingsley R. Chin, MD, founded KICVentures, a private investment company, in 2005.
More articles on biologics:
Cerapedics receives FDA IDE approval for study of P-15L Bone Graft in TLIF surgery: 4 things to know
Drs. Kevin Pauza, Gregory Lutz launch study into non-invasive degenerated disc treatment: 5 highlights
4 things to know about mensenchymal stromal cells in spine
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
